Table of Contents Table of Contents
Previous Page  279 / 916 Next Page
Show Menu
Previous Page 279 / 916 Next Page
Page Background

25th European Congress of Psychiatry / European Psychiatry 41S (2017) S238–S302


– scored 1-2 on the Clinical Global Impression Scale;

– showed a greater than 25% reduction of the total score on the

Positive and Negative Syndrome Scale (PANSS) or a greater than

20% reduction on the negative subscale of PANSS.

Forty-seven patients were randomized: treatment group (neu-

roleptic +memantine,


= 24), control group (neuroleptic + placebo,


= 23); 44 patients completed the study. Neither memantine

nor placebo led to a reliable decrease of negative symptoms,

and the groups did not differ from each other. Future studies

should pay more attention not only to the treatment of already

formed negative and cognitive symptoms, but the prevention of

their occurrence. Including through antagonists of N-methyl-



aspartate receptors.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.


Cannabis use in a first onset psychosis

sample: Prevalence and clinical

differences in relation to age of onset

M. Pardo

1 ,

, J. Matalí


, A. Butjosa


, V. Regina


, M. Dolz



J. Usall



Hospital Sant Joan de Déu, Child and Adolescent Psychiatry,

Barcelona, Spain


Parc Sanitari Sant Joan de Deu, Unitat de Recerca i

Desenvolupament, Sant Boi de Llobregat, Spain

Corresponding author.


There is a wide range of studies focusing on the use

of cannabis in first episode psychosis (PEP). Literature using child

and adolescent samples is scarce.

Objectives and aims

To determine the prevalence and clinical dif-

ferences between cannabis users and non-cannabis users of early

onset first episode psychosis (EOP), and adult onset first episode

psychosis (AOP).


One hundred and forty patients were recruited in adult

(AOP subsample,


= 69) and child and adolescent (EOP subsample,


= 71) mental health services. The Positive and Negative Syndrome

Scale was used for psychotic symptoms and the Calgary Scale

for affective symptoms. The Chi


test analysed clinical differences

between users and nonusers within subsamples, and in the total

sample a Pearson correlationwas used for the relationship between

age at cannabis use and PEP.


The prevalence of lifetime use of cannabis and the aver-

age age at first use were 48% and 13.82 years (


1.15) in the EOP

subsample, and 58% and 17.78 years (


3.93) in the AOP subsample.

Within EOP, cannabis users were older (


= .001), had fewer nega-

tive symptoms (


= .045) and less depressive symptoms (


= .005).

Within AOP, cannabis users were younger (


= .018) and had greater

severity of positive symptoms (


= .021). Age at first cannabis use

and age at PEP were positively correlated.


Cannabis use is prevalent in adult and early onset

psychosis. Cannabis users differ clinically from non-users, and the

earlier the use of cannabis, the earlier the onset of psychosis.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.


The regional project for the treatment

of early psychosis implemented in the

Reggio Emilia Mental Health

Department: Preliminary data from a

2-year follow-up

L. Pelizza

, A. Raballo , E. Semrov , S. Azzali , S. Garlassi ,

F. Paterlini , I. Scazza , F. Fontana , R. Favazzo , M. Fabiani ,

L. Pensieri , V. Barbanti Silva , L. Cioncolini

Reggio Emilia Public Health Service, Reggio Emilia Department of

Mental Health, Reggio Emilia, Italy

Corresponding author.


Several studies had shown the effectiveness of com-

bined interventions in the treatment of young patients with a first

episode of psychosis (FEP). More controversial are the evidence

about the stability of the therapeutic outcomes in individuals ultra-

high risk (UHR).


To describe the regional project for the treatment of early

psychosis implemented in the Reggio EmiliaMental Health Depart-

ment (ReMHD) and also to report preliminary data from a 2-year



In addition with the treatment as usual (TAU), treat-

ment implemented within the regional project for early psychosis

(PREP) in the ReMHD comprises the following:

– pharmacotherapy according to international guidelines;

– a phase-specific individualized Cognitive-Behavioural therapy;

– a psycho-educational intervention addressed to familymembers;

– a case management recovery-oriented.

Action strategies are preceded by the administration of Reggio

Emilia at Risk mental States Battery Checklist as a comprehensive

assessment useful to define the severity and the quality of symp-

toms, the degree of functioning, the subjectivity of suffering, and

the perceived quality of life.


The assessment carried out after 24months of continuous

treatment showed significant improvements in both the psychotic

symptoms (positive, negative and general psychopathology PANSS

subscales) that the daily functioning (SOFAS).


Although our sample is still relatively small (


= 50)

to draw definitive conclusions, it is emerging the good progno-

sis for UHR individuals and patients with FEP submitted on PREP

treatment implemented in the ReMHD.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.


Neuropsychological profile of specific

executive functions in patients with

deficit and non-deficit schizophrenia

J. Pelka-Wysiecka

1 ,

, T. Ernest


, M. Monika


, S. Jerzy



Pomeranian Medical University, Psychiatry, Szczecin, Poland


University of Szczecin, Department of Clinical Psychology- Institute

of Psychology, Szczecin, Poland


Pomeranian Medical University, Independent Clinical Psychology

Unit- Department of Psychiatry, Szczecin, Poland

Corresponding author.

Although it has been shown that there are more profound deficits

present in the deficit schizophrenia (DS) patients compared with

their non-deficit (NDS) counterparts, there still remain a few mat-

ters that require further investigation.


(1) Comparison of executive functions between the inves-

tigated groups; (2) determining the relationship between their

particular aspects within the groups; and (3) drawing up their neu-

ropsychological profile.


One hundred and forty-eight schizophrenia patients,

divided into two groups: patients with DS (


= 70) and NDS (


= 78).

Patients were matched for sex, age, number of years of education

and their overall cognitive functioning. For the assessment of exec-

utive function, we used the Wisconsin Card Sorting Test (WCST),

the Trail Making Test (TMT), Verbal Fluency Test Phonemic (VFT P),

Stroop Color Word Test (SCWT) and Go/No Go task (GNG).


The DS patients compared with the NDS ones obtained

lower scores in WCST and TMT (relative flexibility). We did not